RU2016142225A - Иммуноглобулины к cd52 человека - Google Patents
Иммуноглобулины к cd52 человека Download PDFInfo
- Publication number
- RU2016142225A RU2016142225A RU2016142225A RU2016142225A RU2016142225A RU 2016142225 A RU2016142225 A RU 2016142225A RU 2016142225 A RU2016142225 A RU 2016142225A RU 2016142225 A RU2016142225 A RU 2016142225A RU 2016142225 A RU2016142225 A RU 2016142225A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- antibody
- binding fragment
- antigen binding
- sequences
- Prior art date
Links
- 102000013135 CD52 Antigen Human genes 0.000 title claims 4
- 108010065524 CD52 Antigen Proteins 0.000 title claims 4
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 229940072221 immunoglobulins Drugs 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 45
- 239000000427 antigen Substances 0.000 claims 37
- 102000036639 antigens Human genes 0.000 claims 37
- 108091007433 antigens Proteins 0.000 claims 37
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 18
- 238000000034 method Methods 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 claims 12
- 102000043738 human CD52 Human genes 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 10
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010029113 Neovascularisation Diseases 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical class N[C@@H](C)C(=O)* 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17783709P | 2009-05-13 | 2009-05-13 | |
| US61/177,837 | 2009-05-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011150516/10A Division RU2603743C2 (ru) | 2009-05-13 | 2010-05-13 | Иммуноглобулины k cd52 человека |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016142225A true RU2016142225A (ru) | 2018-12-18 |
Family
ID=43085579
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016142225A RU2016142225A (ru) | 2009-05-13 | 2010-05-13 | Иммуноглобулины к cd52 человека |
| RU2011150516/10A RU2603743C2 (ru) | 2009-05-13 | 2010-05-13 | Иммуноглобулины k cd52 человека |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011150516/10A RU2603743C2 (ru) | 2009-05-13 | 2010-05-13 | Иммуноглобулины k cd52 человека |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US8617554B2 (enExample) |
| EP (3) | EP2998405B1 (enExample) |
| JP (4) | JP5894912B2 (enExample) |
| KR (5) | KR20160005143A (enExample) |
| CN (3) | CN104231084B (enExample) |
| AR (1) | AR076770A1 (enExample) |
| AU (1) | AU2010249003B2 (enExample) |
| BR (1) | BRPI1013085A2 (enExample) |
| CA (2) | CA2939492C (enExample) |
| HK (2) | HK1222682A1 (enExample) |
| IL (2) | IL216141B (enExample) |
| MX (1) | MX2011012047A (enExample) |
| MY (1) | MY160126A (enExample) |
| NZ (2) | NZ621170A (enExample) |
| RU (2) | RU2016142225A (enExample) |
| SG (2) | SG176060A1 (enExample) |
| TW (3) | TW201825115A (enExample) |
| WO (1) | WO2010132659A2 (enExample) |
| ZA (1) | ZA201108077B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9669057B2 (en) | 2008-04-25 | 2017-06-06 | Duke University | Regulatory B cells and their uses |
| EP3345620B1 (en) | 2009-05-13 | 2024-08-28 | Genzyme Corporation | Methods and compositions for treating lupus |
| JP5894912B2 (ja) * | 2009-05-13 | 2016-03-30 | ジェンザイム・コーポレーション | 抗ヒトｃｄ５２免疫グロブリン |
| US9814740B2 (en) * | 2010-12-21 | 2017-11-14 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
| JP6104794B2 (ja) * | 2011-04-18 | 2017-03-29 | 国立大学法人 東京大学 | 抗ｉｔｍ２ａ抗体を用いる癌の診断および治療 |
| GB201109238D0 (en) * | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
| EA034989B1 (ru) | 2011-10-28 | 2020-04-15 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон |
| WO2013185165A1 (en) * | 2012-06-14 | 2013-12-19 | The Walter And Eliza Hall Institute Of Medical Research | Cd-52 antibodies and their use in determining and enhancing an immune response in a subject |
| US10017739B2 (en) | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
| WO2014066271A1 (en) * | 2012-10-22 | 2014-05-01 | Becton, Dickinson And Company | Non-b-lineage cells capable of producing antibody |
| EP2970496B1 (en) * | 2013-03-12 | 2018-07-18 | Institute of Arthritis Research LLC | Immunologically active polypeptide |
| PE20152004A1 (es) | 2013-03-13 | 2016-02-07 | Prothena Biosciences Ltd | Inmunoterapia tau |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| KR102042174B1 (ko) | 2013-03-29 | 2019-11-08 | 삼성전자주식회사 | 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도 |
| KR102060540B1 (ko) * | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
| KR20150139955A (ko) | 2013-04-09 | 2015-12-14 | 보스톤 바이오메디칼, 인크. | 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온 |
| KR102186363B1 (ko) * | 2013-09-06 | 2020-12-04 | 삼성전자주식회사 | c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물 |
| KR102192591B1 (ko) * | 2013-09-09 | 2020-12-18 | 삼성전자주식회사 | c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물 |
| BR112017026025A2 (pt) | 2015-06-03 | 2018-08-14 | Boston Biomedical Inc | composições que compreendem um inibidor de stemness de câncer e um agente imunoterápico para uso no tratamento de câncer |
| SG11201809331RA (en) | 2016-05-02 | 2018-11-29 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| PE20190261A1 (es) | 2016-05-02 | 2019-02-25 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| US11299469B2 (en) | 2016-11-29 | 2022-04-12 | Sumitomo Dainippon Pharma Oncology, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| JP7252627B2 (ja) | 2016-12-15 | 2023-04-05 | デューク ユニバーシティ | 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用 |
| WO2018195457A2 (en) | 2017-04-21 | 2018-10-25 | Genzyme Corporation | Treatment of multiple sclerosis with anti-cd52 antibodies |
| IL270375B2 (en) | 2017-05-02 | 2024-12-01 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| US10646464B2 (en) | 2017-05-17 | 2020-05-12 | Boston Biomedical, Inc. | Methods for treating cancer |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| CA3086009A1 (en) * | 2017-12-20 | 2019-06-27 | Radimmune Therapeutics, Inc. | Antibodies to centrin-1, methods of making, and uses thereof |
| SG11202106483WA (en) | 2018-12-19 | 2021-07-29 | Humabs Biomed Sa | Antibodies that neutralize hepatitis b virus and uses thereof |
| SI3897672T1 (sl) | 2018-12-20 | 2024-02-29 | Humabs Biomed Sa | Kombinirana terapija HBV |
| AU2020231366A1 (en) | 2019-03-03 | 2021-08-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CN109929835A (zh) * | 2019-03-27 | 2019-06-25 | 中国人民解放军第四军医大学 | 一种鼠单克隆抗体功能轻链可变区基因的扩增方法 |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| JP7678768B2 (ja) * | 2019-07-02 | 2025-05-16 | テリックス ファーマシューティカルズ （イノベーションズ） ピーティーワイ リミテッド | 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体 |
| WO2021223719A1 (zh) * | 2020-05-08 | 2021-11-11 | 亘喜生物科技（上海）有限公司 | 一种抗cd19抗体的抗体及其制备和应用 |
| CA3199001A1 (en) * | 2020-11-19 | 2022-05-27 | Victor R. Cairns | Flow cytometry attenuated reporter expression (flare) multiple reporter system and methods of use thereof |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2025031965A1 (en) * | 2023-08-04 | 2025-02-13 | Cimeio Therapeutics Ag | Discernible cell surface protein variants of cd52 for use in cell therapy |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1987006265A1 (fr) | 1986-04-17 | 1987-10-22 | Kyowa Hakko Kogyo Co., Ltd. | Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| GB2216126B (en) | 1988-02-12 | 1992-06-03 | Medical Res Council | Antibodies to the antigen campath-1 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質ｄｃ１１３ |
| JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Ｄｃ―８８ａ誘導体 |
| US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| GB9022547D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
| GB9108056D0 (en) * | 1991-04-16 | 1991-06-05 | Hale Geoffrey | Synthetic antigen |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| US5269388A (en) | 1991-11-12 | 1993-12-14 | Stress-Tek, Inc. | Weighing bed |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
| EP0705833B1 (en) | 1994-04-22 | 2004-07-21 | Kyowa Hakko Kogyo Co., Ltd. | Dc-89 derivative |
| US5550246A (en) | 1994-09-07 | 1996-08-27 | The Scripps Research Institute | Calicheamicin mimics |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| DK1242401T3 (da) | 1999-11-24 | 2007-05-07 | Immunogen Inc | Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf |
| IL151499A0 (en) | 2000-03-03 | 2003-04-10 | Cambridge Antibody Tech | Human antibodies against eotaxin and their use |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| US20020132983A1 (en) * | 2000-11-30 | 2002-09-19 | Junghans Richard P. | Antibodies as chimeric effector cell receptors against tumor antigens |
| AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| WO2004042032A2 (en) | 2002-11-01 | 2004-05-21 | The Ohio State University Research Foundation | Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia |
| CN1225480C (zh) * | 2002-12-18 | 2005-11-02 | 马菁 | 抗cd52单克隆抗体、其编码序列及应用 |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| JPWO2004087210A1 (ja) * | 2003-03-31 | 2006-06-29 | 麒麟麦酒株式会社 | 抗ｃｄ５２抗体による調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物 |
| WO2005017149A1 (en) | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| JP4804357B2 (ja) | 2003-11-01 | 2011-11-02 | メルク パテント ゲーエムベーハー | 改変抗ｃｄ５２抗体 |
| US20060204496A1 (en) * | 2003-11-28 | 2006-09-14 | Tetsuo Kojima | Agonist antibody against heteroreceptor |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| AU2005282720B2 (en) * | 2004-09-02 | 2011-08-04 | Genentech, Inc. | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| US7655229B2 (en) | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| EP3520815B1 (en) | 2005-02-08 | 2021-11-17 | Genzyme Corporation | Antibodies to tgfbeta |
| RU2007147414A (ru) * | 2005-05-24 | 2009-07-10 | Эйвестаджен Лимитед,In (In) | Способ рекомбинантного получения моноклонального антитела к cd52, предназначенного для лечения хронического лимфолейкоза |
| SI1888113T1 (sl) | 2005-05-27 | 2014-10-30 | Biogen Idec Ma Inc. | Protitelesa, ki veĹľejo TWEAK |
| EP1966244B1 (en) * | 2005-12-30 | 2012-03-21 | Merck Patent GmbH | Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130 |
| PL2012814T3 (pl) * | 2006-04-12 | 2013-10-31 | Genzyme Corp | Sposoby leczenia chorób autoimmunologicznych |
| RS54658B1 (sr) | 2006-09-13 | 2016-08-31 | Alcafleu Management Gmbh & Co. Kg | Lečenje multiple skleroze (ms) sa kampat-1 h |
| EP2056838B1 (en) | 2007-02-28 | 2013-09-25 | Merck Sharp & Dohme Corp. | Combination therapy for treatment of immune disorders |
| JP2010530857A (ja) * | 2007-06-22 | 2010-09-16 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 神経系障害、特に感染性海綿状脳症及びアルツハイマー病を治療するためのｃｄ５２抗原に対する抗体の使用 |
| US20120058082A1 (en) | 2009-05-13 | 2012-03-08 | Genzyme Corporation | Methods and compositions for treatment |
| EP3345620B1 (en) | 2009-05-13 | 2024-08-28 | Genzyme Corporation | Methods and compositions for treating lupus |
| JP5894912B2 (ja) | 2009-05-13 | 2016-03-30 | ジェンザイム・コーポレーション | 抗ヒトｃｄ５２免疫グロブリン |
| CN105440133A (zh) | 2009-07-15 | 2016-03-30 | Aimm医疗股份公司 | 革兰氏阳性细菌特异性结合化合物 |
| KR102318383B1 (ko) | 2010-07-16 | 2021-10-27 | 아디맵 엘엘씨 | 항체 라이브러리 |
| ITMI20110376A1 (it) | 2011-03-10 | 2012-09-11 | Wilic Sarl | Aerogeneratore raffreddato a fluido |
| GB201109238D0 (en) | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
| AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| ES2838680T3 (es) | 2014-10-09 | 2021-07-02 | Genzyme Corp | Conjugados de anticuerpo-fármaco glucomodificados |
| WO2018195457A2 (en) | 2017-04-21 | 2018-10-25 | Genzyme Corporation | Treatment of multiple sclerosis with anti-cd52 antibodies |
-
2010
- 2010-05-13 JP JP2012511010A patent/JP5894912B2/ja active Active
- 2010-05-13 KR KR1020157036932A patent/KR20160005143A/ko not_active Withdrawn
- 2010-05-13 KR KR1020147020065A patent/KR20140102764A/ko not_active Withdrawn
- 2010-05-13 CA CA2939492A patent/CA2939492C/en active Active
- 2010-05-13 EP EP15191351.4A patent/EP2998405B1/en active Active
- 2010-05-13 AU AU2010249003A patent/AU2010249003B2/en not_active Ceased
- 2010-05-13 NZ NZ621170A patent/NZ621170A/en not_active IP Right Cessation
- 2010-05-13 KR KR1020177026871A patent/KR20170113704A/ko not_active Ceased
- 2010-05-13 KR KR1020167022759A patent/KR20160103160A/ko not_active Ceased
- 2010-05-13 AR ARP100101677A patent/AR076770A1/es not_active Application Discontinuation
- 2010-05-13 CA CA2761800A patent/CA2761800C/en active Active
- 2010-05-13 SG SG2011083847A patent/SG176060A1/en unknown
- 2010-05-13 SG SG10201608169QA patent/SG10201608169QA/en unknown
- 2010-05-13 CN CN201410379748.7A patent/CN104231084B/zh active Active
- 2010-05-13 TW TW106123171A patent/TW201825115A/zh unknown
- 2010-05-13 NZ NZ596384A patent/NZ596384A/en not_active IP Right Cessation
- 2010-05-13 RU RU2016142225A patent/RU2016142225A/ru not_active Application Discontinuation
- 2010-05-13 WO PCT/US2010/034704 patent/WO2010132659A2/en not_active Ceased
- 2010-05-13 KR KR1020117029662A patent/KR101537840B1/ko not_active Expired - Fee Related
- 2010-05-13 EP EP10775530A patent/EP2429582A4/en not_active Withdrawn
- 2010-05-13 US US13/320,019 patent/US8617554B2/en active Active
- 2010-05-13 CN CN2010800312662A patent/CN102459628A/zh active Pending
- 2010-05-13 BR BRPI1013085-3A patent/BRPI1013085A2/pt not_active IP Right Cessation
- 2010-05-13 MX MX2011012047A patent/MX2011012047A/es active IP Right Grant
- 2010-05-13 TW TW099115371A patent/TWI529247B/zh not_active IP Right Cessation
- 2010-05-13 RU RU2011150516/10A patent/RU2603743C2/ru not_active IP Right Cessation
- 2010-05-13 MY MYPI2011005455A patent/MY160126A/en unknown
- 2010-05-13 TW TW104144762A patent/TWI614267B/zh not_active IP Right Cessation
- 2010-05-13 EP EP19214547.2A patent/EP3683317A3/en not_active Withdrawn
- 2010-05-13 CN CN201910228216.6A patent/CN110016081A/zh active Pending
-
2011
- 2011-11-03 IL IL216141A patent/IL216141B/en not_active IP Right Cessation
- 2011-11-03 ZA ZA2011/08077A patent/ZA201108077B/en unknown
-
2012
- 2012-09-10 HK HK16110806.5A patent/HK1222682A1/en unknown
-
2013
- 2013-11-26 US US14/091,083 patent/US20140341910A1/en not_active Abandoned
-
2014
- 2014-07-16 JP JP2014145770A patent/JP2014195474A/ja not_active Withdrawn
-
2015
- 2015-06-18 HK HK15105820.8A patent/HK1205152A1/xx unknown
- 2015-09-24 US US14/864,736 patent/US20160208010A1/en not_active Abandoned
-
2016
- 2016-02-10 JP JP2016023418A patent/JP2016093194A/ja not_active Withdrawn
-
2017
- 2017-12-01 JP JP2017231850A patent/JP2018029624A/ja not_active Withdrawn
-
2018
- 2018-10-28 IL IL262639A patent/IL262639A/en unknown
-
2019
- 2019-04-10 US US16/380,389 patent/US20200040091A1/en not_active Abandoned
-
2021
- 2021-03-03 US US17/191,440 patent/US11945874B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016142225A (ru) | Иммуноглобулины к cd52 человека | |
| JP2012526558A5 (enExample) | ||
| US12226482B2 (en) | Anti-SIRP-alpha antibodies and methods of use thereof | |
| RU2693661C2 (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| AU2016339832B2 (en) | Antibody agents specific for human CD19 and uses thereof | |
| CN112969714B (zh) | 抗cd40抗体、其抗原结合片段及其医药用途 | |
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| TW202337907A (zh) | 對ｆｌｔ３具特異性之抗體及其用途 | |
| CN110431151A (zh) | 仅有重链的抗bcma抗体 | |
| US20070110754A1 (en) | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia | |
| JP2008509080A (ja) | アンタゴニスト抗ｃｄ４０モノクローナル抗体およびその使用方法 | |
| US12227583B2 (en) | Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use | |
| CN114072172B (zh) | 靶向人cd47的抗体 | |
| CA2789810A1 (en) | Compositions and methods for targeting type 1 interferon-producing cells | |
| CN113382752A (zh) | Cd137激动剂抗体及其用途 | |
| WO2019200255A1 (en) | High-affinity mycobacterium tuberculosis capsule-specific human monoclonal antibody | |
| CN113150150B (zh) | Tim3结合分子及其应用 | |
| WO2022228545A1 (en) | Antibodies and variants thereof against human 4-1bb | |
| WO2024175020A1 (en) | Anti-il2ra antibodies and uses thereof | |
| WO2024218650A1 (en) | Lilrb1 and lilrb2 antibodies and methods of use thereof | |
| US20230042316A1 (en) | Monoclonal antibodies that target human cd47 protein | |
| EP4532546A1 (en) | Anti-tnfr2 antibodies and methods of use thereof | |
| TW202523701A (zh) | 用於治療癌症之ｓｉｒｐ抗體 | |
| JP2025084100A (ja) | 抗ｔｎｆｒ２抗体およびその使用の方法 | |
| WO2025226691A1 (en) | Sirp alpha and beta antibodies for treatment of epstein–barr virus infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20191028 |